Pharma

Phase 3 TRIUMPH trials showed retatrutide cut knee pain by up to 75.8% with some patients pain‑free; TOGETHER‑PsA found ixekizumab plus tirzepatide raised ACR50 to 43.7% at 52 weeks.

Real‑world analysis of 544,103 adults with ASCVD followed up to four years; comparative non‑statin outcomes evidence to inform treatment choices and LDL‑C goal attainment.

Revenue rose 22% to $3,238m; epcoritamab approved in Europe and Japan; two Phase‑3 starts for petosemtamab in CRC; multiple Phase‑3 topline readouts were positive.

Long-term Hibsago data and efimosfermin Phase II fibrosis signals headline 21 abstracts at AASLD (5–9 Nov, Denver). Findings span functional cure durability, HBsAg predictors and retreatment modelling.

GLP‑1 volume growth drove sales and adjusted profit; reported profit hit by USD 1.4bn impairments; Wegovy and Ozempic pills expand launches while late‑stage pipeline advances.

China’s NMPA cleared an oral, reversible HER2‑targeting TKI for first‑line use in unresectable or metastatic HER2‑mutant NSCLC based on Phase I/II ORR and DOR data.

GLP‑1 volume growth drove sales and margin expansion; reported profit hit by non‑cash impairments; Wegovy and Ozempic pill rollouts broadened; pipeline milestones support near‑term launches.

Total revenues rose 8% to $10.4B; GAAP EPS $7.08; 17 products annualizing >$1B; full-year revenue guidance $38.9–$39.7B with up to $3.0B share repurchases.

Pharma growth driven by Nubeqa and Kerendia; asundexian cleared in China; Group raises Pharma margin and Group EBITDA-before-special-items guidance, improves cash and debt outlook.

Randomized Phase 3 will enroll ~2,136 adults on standard COPD therapy to test whether add-on ensifentrine reduces annualized moderate/severe exacerbation rate over 52 weeks.